News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Suspends Hepatitis C Drug Clinical Trial


8/2/2012 6:55:15 AM

PRINCETON, N.J., Aug 01, 2012 (BUSINESS WIRE) -- Bristol-Myers Squibb Company announced today that the Company has suspended study drug administration in an ongoing Phase II study of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C. This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue. The cause of the safety issue and any potential relationship to study drug are unknown at this time.

With patient safety as the priority, the Company is undertaking an immediate assessment of all patients in the study and following an evaluation of the patient data, will take appropriate actions.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews .

SOURCE: Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Media:

Sonia Choi, 609-252-5132

sonia.choi@bms.com

or

Investors:

John Elicker, 609-252-4611

john.elicker@bms.com

or

Timothy Power, 609-252-7509

timothy.power@bms.com


Read at BioSpace.com
Read at BusinessWeek
Read at Boston Globe
Read at The Street.com
Read at Reuters

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES